Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome by Nielsen, Sarah M et al.




Nielsen et al.  1 
 
Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple 1 
Neoplasia Syndrome 2 
Sarah M. Nielsen1, Lindsay Rhodes2, Ignacio Guillermo Blanco3, Wendy K. Chung4, Charis 3 
Eng5,6, Eamonn R. Maher7, Stéphane Richard8, and Rachel H. Giles10, 11 4 
1Center for Clinical Cancer Genetics and Global Health, Department of Medicine, The 5 
University of Chicago, Chicago, IL, 60637 USA 6 
2Department of Pediatrics, The University of Chicago, Chicago, IL 60637 USA 7 
 8 
3Spanish Association of Human Genetics, Hospital Universitari Germans Trias i Pujol, UAB - 9 
Universitat Autònoma de Barcelona, Barcelona, Spain 10 
4Departments of Pediatrics and Medicine, Columbia University, New York, NY 10032 USA 11 
5Genomic Medicine Institute, Lerner Research Institute and Taussig Cancer Institute, Cleveland 12 
Clinic, Cleveland, OH 44195 USA 13 
 14 
6Department of Genetics and Genome Sciences and Germline High Risk Focus Group, CASE 15 
Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 16 
Cleveland, OH 44106 USA 17 
 18 
7Department of Medical Genetics, University of Cambridge and Cambridge NIHR Biomedical 19 
Research Centre, Cambridge CB2 0QQ, UK 20 
 21 
8Centre Expert National Cancers Rares PREDIR, INCa/AP-HP, Hôpital Bicêtre, 94275 Le 22 
Kremlin Bicêtre ; Génétique Oncologique EPHE, INSERM U1186, Gustave Roussy Cancer 23 
Campus, 94800 Villejuif-France 24 
 25 
10Department of Nephrology, University Medical Center Utrecht, Regenerative Medicine Center 26 
Utrecht, Uppsalalaan 6, 3584CT Utrecht, The Netherlands 27 
 28 









Nielsen et al.  2 
 
Running Head: Genetics of VHL Disease and Genetic Counseling Considerations    34 
Key Words: VHL, genetics, genetic counseling, multiple neoplasia syndromes, genotype-35 
phenotype correlation 36 
Word Count: 5,219 37 
Corresponding Author: 38 
Sarah Nielsen, MS, CGC 39 
The University of Chicago Medicine & Biological Sciences 40 
5841 S. Maryland Ave., MC 2115, Chicago, IL, 60637 41 
Office: 773-702-4749 42 
Fax: 773-834-3834 43 


















Nielsen et al.  3 
 
Abstract  58 
 59 
Von Hippel-Lindau disease (VHL) is one of the most common inherited neoplasia syndromes 60 
characterized by highly vascular tumors of the eyes, brain and spine, as well as benign and 61 
malignant tumors and/or cysts of the kidneys, adrenal medullae/sympathetic paraganglia, 62 
endolymphatic sac, epididymis, and broad ligament. Since the discovery of the VHL gene in 63 
1993, >900 families with VHL have been identified and examined. Genetic testing for VHL is 64 
widely available and will detect a disease-causing mutation in rate 95-100% of individuals who 65 
have a clinical diagnosis of VHL, making it the standard of care for diagnosis of VHL. 66 
Furthermore, genetic testing for VHL is indicated in some individuals with apparently sporadic 67 
VHL-related tumor types since ≤10% of pheochromocytoma or early-onset renal cell carcinoma 68 
(personal communication, Dr. Brian Shuch) and up to 40% of CNS hemangioblastoma harbor 69 
germline VHL mutations without a family history or additional features of VHL disease.1,2 The 70 
majority of VHL mutations are private, but there are also well-characterized founder mutations. 71 
VHL is a complex, multi-organ disease which spans the breadth of oncology subspecialties, and 72 
as such, providers in these subspecialties should be aware of 1) when to consider a diagnosis of 73 
VHL, 2) when to refer to a genetics specialist for consideration of gene testing, and perhaps most 74 
importantly, 3) how to communicate this sensitive information in an age-appropriate manner to 75 
at-risk families. This manuscript will provide state of the art information on the genetics of VHL 76 
and will serve as a key reference for non-genetics professionals who encounter VHL patients.  77 
 78 
 79 
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Von Hippel-Lindau disease (VHL) is an inherited multiple-neoplasia syndrome 80 
characterized by highly vascular tumors of the eyes, brain and spine (retinal and CNS 81 
hemangioblastomas; HB), as well as benign and malignant tumors and/or cysts of the kidneys 82 
(clear cell renal cell carcinoma; RCC), adrenal glands/sympathetic paraganglia 83 
(pheochromocytoma; PCC, paraganglioma; PGL), pancreas (cysts/cystadenomas or pancreatic 84 
neuroendocrine tumors; PNETs), endolymphatic sac (endolymphatic sac tumors; ELSTs), 85 
epididymis (epididymal cysts and cystadenomas), and broad ligament (broad 86 
ligament/mesosalpinx cystadenoma).3-6 Since the first description of the disease in 1926 7 and the 87 
discovery of the VHL gene over 60 years later 8, >900 families worldwide with VHL have been 88 
identified and examined.9,10  89 
A timely review of the genetics of VHL is warranted because genetics is becoming 90 
increasingly integrated into healthcare in the name of “personalized” or “precision” medicine; as 91 
such, health care providers must now more than ever understand the sensitive and unique nature 92 
of communicating genetic information to patients. This is especially true in the field of oncology, 93 
where both somatic and germline genetic testing is becoming a standard part of oncologic work-94 
up and clinical care.  In the context of VHL, it is important to consider the sensitive nature of 95 
pre-symptomatic testing of children, as well as “unexpected” (incidental) VHL diagnoses as a 96 
result of the incorporation of multi-gene next-generation sequencing panels into clinical practice 97 
for sporadic VHL-associated tumors, namely RCC and PCC/PGL. Other special considerations 98 
in VHL include preconception counseling (including pregnancy-related risks), and the burden of 99 
extensive clinical screening.  100 
 101 
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Clinical Diagnosis and VHL Gene 102 
A VHL diagnosis is established in an individual with a family history of VHL when they 103 
present with a single characteristic VHL-related tumor (e.g. retinal or cerebellar HB, RCC etc.). 104 
In the absence of a family history of VHL, a diagnosis requires two or more retinal or cerebellar 105 
HB, or one HB and a visceral tumor (excluding epididymal and renal cysts which are common in 106 
the general population).3,11-13 107 
 The VHL tumor suppressor gene (VHL) was mapped to 3p25-26 in 1993.8 Individuals 108 
with the hereditary form of these tumors inherit a single mutant VHL allele, and tumor 109 
development occurs when the second wild-type copy is spontaneously lost or inactivated. This 110 
“second hit” can occur through a variety of mechanisms, including point mutations, deletions, or 111 
promoter hypermethylation.14 As with many predisposition genes causing rare inherited cancer 112 
syndromes, somatic loss-of-function of VHL occurs in sporadic cancers.15-17 Indeed, inactivation 113 
of VHL is a critical driver of nearly all clear-cell RCC, 18,19 approximately 40% of sporadic CNS 114 
HB and 10% of sporadic PCC.20-23  115 
Molecular Biology of VHL 116 
Over two decades of research has implicated VHL protein (pVHL) in transcriptional 117 
regulation, apoptosis, extracellular matrix formation, and ubiquitinylation of specific targets.23 In 118 
particular, the role of pVHL in the adaptive cellular response to hypoxia has been robustly 119 
investigated; pVHL regulates hypoxia-inducible genes through the targeted ubiquitinylation and 120 
degradation of the alpha-subunits of the hypoxia-inducible factor transcription factors (HIF-1α, -121 
2α, -3α). 122 
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pVHL binds to elongin C, which forms a complex with elongin B, cullin-2 and Rbx1. 123 
This complex catalyzes the polyubiquitinylation of specific proteins and targets them for 124 
proteosomal degradation. Under normoxic conditions, HIFα subunits are hydroxylated by prolyl 125 
hydroxylases, a reaction requiring oxygen. The VHL protein then binds to hydroxylated HIFα, 126 
targeting it for degradation by its attached destruction complex. In the absence of oxygen or 127 
functional pVHL, HIFα subunits are stabilized, accumulate, and translocate to the nucleus where 128 
HIFα forms heterodimers with HIFβ to activate the transcription of dozens of hypoxia-inducible 129 
genes (i.e., VEGF, EPO, TGFα, PDGFβ).23 VHL-mutant cells experience pseudo-hypoxia and 130 
shift metabolism to glycolysis even in the presence of oxygen, a process referred to as the 131 
Warburg effect. In fact, our ability to better manage patients with non-familial advanced renal 132 
cell carcinoma as well as surgical management guidelines of small renal masses has been largely 133 
driven by a better understanding of the VHL and consequent biochemical alterations underlying 134 
these tumors, in particular first-line VEGF-targeting agents.24 135 
Pathogenic variants in VHL either reduce expression (i.e., deletions, frameshifts, 136 
nonsense variants, and splice site variants) or lead to the expression of an abnormal protein (i.e., 137 
pathogenic missense variants). The type of VHL that results from a pathogenic missense variant 138 
depends on its effect on the three-dimensional structure of the protein.25 Pathogenic variants in 139 
VHL cause misfolding and subsequent chaperonin-mediated breakdown.26 Pathogenic missense 140 
variants that destabilize packing of the alpha-helical domains, decrease the stability of the alpha-141 
beta domain interface, interfere with binding of elongin C and HIFα, or disrupt hydrophobic core 142 
residues result in loss of HIF regulation. Furthermore, mutant pVHL may predispose to 143 
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pheochromocytoma by altering the molecular regulation of apoptosis of sympatho-adrenal 144 
precursor cells during development.27 145 
HIF-independent pVHL functions have added greater breadth to the understanding of the 146 
pathophysiology of VHL. For example, cyst formation in VHL patients has been linked 147 
microtubule-based organelles called primary cilia. pVHL directs microtubule orientation and 148 
subsequent stability.28-30 pVHL also regulates primary cilia, through both HIF- and microtubule-149 
independent functions.31-33 Furthermore, genetic instability in tumors is driven by VHL loss.34  150 
pVHL has been shown to mediate in the transcriptional regulation of the nuclear factor 151 
NF-κB35, the Rbp1 large subunit of the RNA polymerase complex II36,37, the p53 tumor 152 
suppressor38, the p400 chromatin remodeling factor39and the JunB transcription factor via 153 
aPKC.27,40 However pVHL also plays an important transcription-independent role in the 154 
regulation of the extracellular matrix and the microtubule cytoskeleton. pVHL is involved in the 155 
correct formation and turnover of the extracellular matrix41 by interacting with collagen IV42 and 156 
fibronectin.43 C. elegans vhl-1 knock out worms also displayed genetic evidence for defects in 157 
ECM formation.44 Furthermore, the activity of enzymes involved in degradation and remodeling 158 
of the ECM, matrix metalloproteinases MMP-2 and MMP-945, is increased in VHL-mutant cells, 159 
and HIF-2α induces the expression of membrane type 1-MMP. Since endothelial cells require 160 
pVHL for correct vascular patterning and maintenance of vascular integrity during 161 
development46, loss of pVHL function causes both HIF-independent and HIF-dependent defects 162 
in the ECM that may promote angiogenesis, invasion and metastasis of tumor cells.41   163 
  The development of malignant disease after biallelic inactivation of VHL has only been 164 
adequately addressed in the context of renal cell carcinoma. Several RCCs sequenced in two 165 




Nielsen et al.  8 
 
VHL patients revealed clonally independent and distinct secondary events all converging on the 166 
PI3K-AKT-mTOR signalling pathway, and not characterized by inactivating mutations in p53, 167 
similar to sporadic renal cell carcinomas in the general public.47 Overall there was limited 168 
evidence of intra-tumor heterogeneity in VHL patients, although the number was very small and 169 
requires independent validation.  170 
Role of Genetic Testing, Mutation Frequency and Spectra 171 
The role of genetic testing in VHL is to confirm or exclude a diagnosis in: 1) at-risk 172 
relatives from established VHL kindreds, 2) individuals with suspected clinical diagnoses, or 3) 173 
individuals with atypical presentation or moderate suspicion, keeping in mind that failure to find 174 
a disease-causing mutation does not rule out a clinical diagnosis in scenario 2.  175 
Approximately 200 distinct mutations have been identified in >900 VHL kindreds.9,10,48 176 
The mutation spectrum includes missense (52% of patients), frameshift (13%), nonsense (11%), 177 
large/complete deletions (11%), in-frame deletions or insertions (6%), and splice-site (7%).9 178 
Almost 100% individuals meeting classic VHL criteria with multi-organ involvement carry 179 
identifiable germline VHL mutations; 24% in those meeting criteria with limited VHL 180 
manifestations; and 3.3% in those with VHL-associated tumors but do not meet diagnostic 181 
criteria.49 Unexpected germline VHL mutations can be found in patients with apparently sporadic 182 
VHL-type tumors. VHL germline mutations occur in 30-50% of patients with retinal HB, 4-40% 183 
of patients with CNS HB, 20% of patients with ELST, 3-11% of patients with PCC and 1-2% of 184 
patients with RCC.1-3,50-55 These observations underlie guidelines suggesting genetics evaluation 185 
when certain tumors or clinical features are present. Referral to genetics professionals for 186 
consideration of testing (Table 1) has been suggested for individuals with simplex cases of 187 
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retinal or CNS HB, PCC, or ELST, as well as clear-cell RCC with any of the following features: 188 
1) diagnosed < age 46, 2) bilateral or multifocal tumors, 3) > 1 close relative with clear-cell 189 
RCC.56 Whereas other groups have suggested that, in addition to the above, genetic evaluation is 190 
warranted for individuals with >1 of the following: pancreatic cystadenoma, pancreatic 191 
neuroendocrine tumor, epididymal/adnexal cystadenoma.57  192 
VHL Gene Testing 193 
VHL genetic testing is available at multiple laboratories worldwide (Table 2). Sanger 194 
sequencing of the coding region, along with deletion/duplication analysis, is the gold standard 195 
for analyzing the VHL gene and results in 95-100% detection rate (though mosaicism may cause 196 
false negative test results).58,59 Multiplex ligation-dependent probe amplification (MLPA) is used 197 
for detecting partial and complete gene deletions/duplications.49,60   198 
When there is a high prior-probability of VHL mutation, single gene testing is 199 
appropriate. However, when the genetic differential diagnosis is large, next-generation 200 
sequencing multi-gene panels should be considered in the setting of genetic counseling. This 201 
technology is often utilized for testing apparently sporadic PCC/PGL or familial/early-onset 202 
RCC to determine if there is an inherited component. Thus, referral for genetics evaluation 203 
should be considered for RCC diagnosed < 46 years old61 (though for clinical purposes we often 204 
cast a wider net and consider referral for diagnoses < 50 years old) or with the presence of a 205 
family history or other syndromic features.62 Over 40% PCC/PGL are associated with germline 206 
mutation in any of 12 genes supporting multi-gene panel testing for all cases of PCC/PGL.54  207 
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Many laboratories worldwide now offer “multi-gene” panels targeted towards PCC/PGL 208 
and RCC. It is critical to include genetics professionals in this testing process as they have the 209 
skills to ensure that the appropriate testing method is followed through their astute analysis of the 210 
personal and family history. If more than one syndrome is in the differential diagnosis, they will 211 
review the implications of each syndrome so that the patient is providing true informed consent, 212 
and there are no “surprise” diagnoses. Additionally, genetics teams have expertise in the 213 
interpretation of genetic testing results, which is particularly crucial in the realm of next-214 
generation sequencing as results are often not straightforward and misinterpretation can have 215 
devastating effects on the patient and family.  While positive genetic test results seem relatively 216 
straightforward, there are many issues to consider once a diagnosis has been made. Genetics 217 
professionals can help individuals cope with a diagnosis and develop strategies to share this 218 
information with at-risk family members. A negative genetic test result must be interpreted in the 219 
context of the individual’s personal and family history; very often it DOES NOT rule out a 220 
clinical or a hereditary cause for the cancer/disease in the family. In this instance, an 221 
individualized approach must be taken to further surveillance recommendations, taking into 222 
account personal/family history and patient preferences. Lastly, variants of uncertain significance 223 
(VUS) identified through genetic testing need to be carefully considered. A VUS means a 224 
genetic change is identified, but the significance of that change is unknown. The patient and their 225 
medical team need to understand that these results do not immediately affect medical 226 
management recommendations, which are always based on personal/family history until that 227 
VUS is reclassified, a process that could take several months or years.  228 
Clinical and Genetic Features  229 
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The incidence of VHL is approximately 1 in 36,000.63 It has a penetrance of over 90% by age 65, 230 
with mean age at tumor diagnosis of 26 years (range 1-70).5,64 The breakdown of frequency and 231 
mean age at diagnosis of specific VHL tumor types is outlined in Table 3. Long-term outcomes 232 
in individuals with VHL continue to improve due to improvements in surveillance and treatment 233 
of RCC and CNS HB, the leading causes of morbidity and mortality in VHL.64 Phenotypic 234 
heterogeneity (both inter- and intrafamilial) is a hallmark of VHL.65,66  Clinically, VHL is 235 
classified into type 1 or type 2 disease based on the frequency of RCC and PCC (see Table 4).67-236 
69 Although this classification facilitates genotype-phenotype studies (reviewed elsewhere9), it 237 
has limited clinical utility as kindreds move between subtypes as additional tumors are 238 
discovered.6,23 Briefly, kindreds with truncating mutations or exon deletions infrequently 239 
manifest PCC, and thus usually have type 1 disease characterized by increased incidence of RCC 240 
and retinal/CNS HBs (but not PCC), whereas Type 2 VHL is characterized by missense 241 
mutations predisposing to PCC, some with PCC alone (type 2C) and other families with 242 
additional manifestations.70 As the relationship between genotype and phenotype is still 243 
evolving, it is recommended that all individuals with a diagnosis of VHL follow the same 244 
surveillance protocol, which screens for all possible manifestations of the disease.  245 
As with most tumor suppressors, the majority of VHL mutations are private. However, 246 
recurrent founder mutations are well-documented. The most well-characterized founder 247 
mutations are those originating from Germany: c.T292C (previously c.T505; p.Y98H) in families 248 
from the Black Forest region, and c.T334C (previously c.T547C; p.Y112H) in families from east 249 
central Germany (Leipzig).67,71-75 These families have migrated across Europe and America, 250 
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especially Western Pennsylvania. Both mutations predispose to Type 2A VHL, with a high risk 251 
of PCC, moderate risk of retinal/CNS HB, and low risk of RCC.74,76 252 
A mutation hotspot is at codon 167, due to the presence of CpG dinucleotide with 253 
attendant risks of deamination.69 There have been more than 82 families identified with 254 
mutations at this location, representing ~43% of mutations in American and Canadian families 255 
with VHL type 2.9,59,69 Individuals with mutations at this location have a high risk of developing 256 
PCC (~62%) and RCC.69  257 
 VHL genotype-phenotype correlation is further complicated by a unique congenital 258 
polycythemia syndrome caused by biallelic (homozygous/compound heterozygous) mutations of 259 
the VHL gene without any manifestations of VHL disease.6 The most frequent mutation in this 260 
syndrome is c.C598T (p.R200W).77 Individuals homozygous for this mutation have 261 
polycythemia, pulmonary hypertension, varicose veins, elevated serum VEGF concentrations, 262 
and occasional vertebral hemangiomas.6,78 263 
VHL is inherited in an autosomal dominant manner, with the majority (80%) of cases 264 
being inherited from an affected parent, and up to 20% de novo.79,80 Once a VHL mutation is 265 
identified in a family, it is recommended to offer genetic testing to that individual’s parents (if 266 
they are available) even in the absence of an apparent family history, as family history may 267 
appear to be negative due to reduced penetrance or later age-of-onset, variable expressivity 268 
among family members, or death of an affected parent before onset of symptoms.81 Mosaicism 269 
occurs when a new mutation arises in some but not all tissues, which can result in negative 270 
genetic testing if an unaffected cell or tissue type is sampled.80 There are data suggesting that 271 
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mosaicism is an under-recognized phenomenon in VHL, which could result in an overestimation 272 
of true cases of de novo mutations in probands. Generally, mosaic individuals tend to be more 273 
mildly affected or asymptomatic81, though this is not always the case and mosaicism has been 274 
confirmed in individuals with classic VHL disease as well.82,83 It is now recommended that 275 
additional testing methods be employed to rule out mosaicism in parents of a proband with an 276 
apparent de novo mutation, as well as cases moderately or highly suspicious of VHL in whom 277 
standard testing methods have failed to detect a disease-causing mutation.80-83 Various 278 
techniques have been successful in identifying mosaic mutations.80,82 Alternatively, different 279 
tissue types can be sampled, including skin fibroblasts and oral epithelial cells.81,84 Detection of 280 
mosaicism is critical in terms of confirming a diagnosis and estimating the risk to siblings and 281 
offspring.82,83As next-generation sequencing replaces Sanger sequencing, mosaic cases may be 282 
more easily detected which could provide the data needed to elucidate the true frequency of 283 
mosaicism in VHL.   284 
Genetic Counseling & Surveillance Considerations  285 
Genotype-phenotype issues are only of scientific value at this point and play no role in 286 
clinical or counseling care to the VHL patient. Given the complexity of the disease, a 287 
multidisciplinary approach with coordination of care amongst multiple medical specialists, 288 
including genetics professionals, is essential for individuals with VHL. Although preventative 289 
treatment cannot yet be offered for VHL, it is generally accepted that comprehensive 290 
surveillance programs do improve the outcomes by preventing avoidable morbidity and 291 
mortality.6,85,86 Therefore, genetics professionals may take a more directive approach to their 292 
counseling because of the importance of initiating or continuing screening for gene carriers (and 293 
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discontinuing it for non-carriers).86 At-risk family members who received genetic counseling 294 
were more likely to pursue VHL testing compared to those who were only informed of the 295 
possibility of testing through a relative or written material.87 Genetics professionals can aid 296 
families in the risk communication process and help identify and work through barriers to 297 
genetic testing and follow-up.   298 
Pre-symptomatic testing of children  299 
 Since children of an individual with VHL each have a 50% chance of being affected, the 300 
topic of genetic testing for VHL in children is one that arises often in clinical care. For healthy 301 
children, many professional statements and guidelines support the recommendation that genetic 302 
testing only be pursued if the condition is associated with childhood onset and if a positive result 303 
leads to effective and safe screening and/or interventional options, thereby reducing morbidity 304 
and mortality.88,89 Although the average age of onset of VHL tumors is in the third decade of life, 305 
some patients do develop tumors under the age of 10 and as early as infancy and therefore pre-306 
symptomatic genetic testing in VHL is justified.90 Pre-symptomatic genetic testing also identifies 307 
those children who did not inherit the familial VHL mutation, thus sparing them from a lifetime 308 
of clinical screening.  309 
There are many factors to be considered before pre-symptomatic genetic testing is 310 
pursued.  Genetic testing may be offered to a family with a child who is too young to give their 311 
informed assent, leading to potential loss of autonomy for that child who may grow up with 312 
genetic information that they were not able to elect for themselves.91 Testing can also be 313 
associated with many complex emotions, including anxiety, denial, and guilt on the part of the 314 
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parent who is affected with VHL.87,89 Many families may have lived through the experience of 315 
loved ones developing tumors or other VHL-related complications at young ages that may 316 
impact their coping when their children are found to carry the VHL mutation.87,91 Additionally, 317 
at-risk or affected children may be treated differently than their non-carrier siblings.87,91-93 318 
Surveillance fatigue/burnout should also be considered in families considering testing for VHL 319 
in their children, since the surveillance is initiated in childhood for mutation-positive children 320 
and is lifelong.94 This topic is discussed more extensively in a subsequent section. It is strongly 321 
recommended that genetic counseling for pre-symptomatic genetic testing be conducted by a 322 
genetics professional in a comfortable environment, with the option of having multiple genetic 323 
counseling sessions, as necessary.87,89,91,95 324 
Genetic communication needs of children with VHL    325 
A major question that arises from parents and health professionals is how and when to 326 
inform children of their genetic status. Research specific to communication among families with 327 
VHL is limited, but studies on the communication needs of children with other genetic condition 328 
have found that the majority of patients would have preferred receiving information before the 329 
age of 12 years, ideally between 6 and 10 years of age. The majority parents with VHL want 330 
their children tested either at birth or at least before the age of 10 years.96,97 Adolescents 331 
preferred that the focus of a genetic counseling session be on understanding and managing their 332 
health condition rather than on their reproductive risks. They also identified their parents as their 333 
primary source of genetic information (with doctors or other health professionals coming second 334 
to this) and many wanted to be seen by their health care provider with their parents present.98 335 
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Parents are often unsure of the best way to discuss information regarding a genetic 336 
diagnosis with their children and common concerns include how the information may impact 337 
their child’s self-esteem, coping, and anxiety level.99 Parents may feel overwhelmed by the 338 
information, not knowing how, when, or what information to provide.93 Additionally, they may 339 
feel insecure in their own understanding of that information.98 Studies show that parents feel 340 
guidance and support from health care professionals on how to deliver this information is very 341 
important though often not available.93 An important part of the genetic counseling process is to 342 
discuss with families how they plan to present the information to their children throughout 343 
different stages of their lives.100  344 
Children report their preference of learning about their genetic condition gradually 345 
through open and continuous communication throughout childhood.92 In this way children are 346 
provided with developmentally appropriate information that they can ask questions about and 347 
understand at their own pace, helping them come to terms with their genetic risk in a natural and 348 
self-driven way.93,100 This genetic information then becomes part of the family narrative or 349 
culture; talking about those in the family who are also affected helps normalize the information 350 
by making it part of a shared family identity.92,93,100  351 
In contrast, not acknowledging the genetic condition in the family dissuades children 352 
from asking questions, as they do not want to upset their parents.92,93,99,100 Genetics  professionals 353 
can help facilitate the communication process, elicit any perceived barriers to communication 354 
and provide a safe place for parents to practice these discussions. Resources that provide parents 355 
with techniques, diagrams, and appropriate language to use while communicating with their 356 
children can be developed, and support groups or additional professional psychosocial support 357 
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should be encouraged. 93,100 One such example available to the VHL community is the VHLA 358 
Handbook Kids’ Edition (accessible at http://www.vhl.org/wordpress/patients-359 
caregivers/resources/vhl-handbooks/).  360 
Pre-conception counseling (including pregnancy-related risks) 361 
 The availability of genetic testing for VHL introduces options for couples at-risk of 362 
having a child with VHL, including prenatal diagnosis and pre-implantation genetic diagnosis 363 
(PGD). Although perceptions may vary across countries, the French VHL study group 364 
interviewed 18 women and 13 men with VHL and found that a significant proportion of them (11 365 
women and 11 men; ~70%) intended to use prenatal diagnosis in the case of a pregnancy, 366 
although half of the group would not terminate an affected pregnancy (or were undecided) 367 
because they hoped for better outcomes and treatments in the future for their children compared 368 
with their own experience of VHL.96 PGD uses in-vitro fertilization techniques to identify 369 
genetic mutations within embryos prior to implantation.101 This is a technology that VHL 370 
patients are interested in exploring: 71% of Australian patients (10/14 respondents) viewed it as a 371 
favorable option to avoid having a child with VHL compared to 33% (26/79 respondents) in the 372 
Dutch population.87,102 At least eleven children have already been born using this method from 373 
the French VHL study group, which now comprises 802 individuals living with VHL, 28 of 374 
whom have attempted to have children using PGD (Coupier et al., unpublished data). It is 375 
important that patients understand the practical limitations of PGD, namely cost as many 376 
insurances currently will not cover the service. Additionally, there are limitations to the 377 
technology that must be communicated, including 1) the germline mutation in the family must be 378 
known; 2) there are no data about the effect of IVF-related hormone treatment for egg harvest on 379 
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tumor development; and 3) the process often takes over a year and if a tumor develops in that 380 
period, application of PGD may be delayed or abandoned.  381 
Another factor that complicates reproductive decision making in VHL are the pregnancy-382 
related risks associated with the disease. While generally pregnancy is not considered a 383 
contraindication in VHL patients, certain precautions must be considered. Available studies on 384 
the subject show conflicting results regarding development or progression of tumors and disease-385 
related complications.103-105 It is critical to evaluate for potentially life-threatening complications, 386 
namely PCC or hydrocephalus due to cerebellar HB, before attempting to become pregnant.103 387 
Many groups also advocate for additional screening and monitoring during pregnancy, including 388 
routine evaluation of retinal angiomas, non-contrast MRI during fourth month for CNS lesions, 389 
plasma metanaphrine testing during early, mid and late pregnancy as well as consideration of 390 
delivery via caesarian section to lower the chance of increased intracranial pressure.103,106 As 391 
long as patients are followed closely by a multidisciplinary team, pregnancy is typically a safe 392 
option for women with VHL, but other options such as surrogacy and adoption can also be 393 
explored.  394 
Psychosocial impact of VHL, including burden of lifelong surveillance  395 
There are little data on the psychosocial impact of complex tumor predisposition 396 
syndromes with limited prevention options. However, the data that do exist suggest that a 397 
significant proportion of those affected by VHL and those who care for them experience 398 
clinically important levels of distress.107 Those that experienced the death of a close relative due 399 
to VHL during adolescence were particularly vulnerable. About one-third of participants had 400 
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received professional psychosocial support, and the rest seemed amenable to it.107 Many patients 401 
struggle with the complex medical, social and psychological aspects of VHL, for example, 402 
uncertainty about future tumor development, frustration regarding lifelong screening, strained 403 
relationships with family and partners, difficulty communicating with others about VHL, and 404 
complex decisions regarding childbearing. 87,108  405 
A highly sensitive concern for VHL patients is the burden of lifelong surveillance. 406 
Suggested surveillance guidelines are summarized in Table 5. While surveillance can pick up 407 
early-stage lesions that are amenable to treatment i.e. retinal angiomas, it also identifies lesions 408 
for which there is no immediate clinical benefit i.e. pancreatic cysts, and even findings unrelated 409 
to VHL that require further follow-up.86 For these reasons, most individuals with VHL view 410 
surveillance regimens as a “necessary yet anxiety-provoking burden” that incite a variety of 411 
responses including denial, anger, fear, sadness and anxiety.87 While the uptake of genetic testing 412 
is generally high in VHL families, as many as 60% of identified mutation carriers will be lost to 413 
follow-up 5 years after testing, suggesting that patients’ concerns regarding surveillance are not 414 
being appropriately addressed.90 As current VHL surveillance guidelines are largely based on 415 
expert medical opinion and limited evidence, healthcare providers also struggle with determining 416 
“optimal” surveillance recommendations while also minimizing the patient’s psychological 417 
distress (“scanxiety”) and expenses to the healthcare system.109  418 
Recently, nationwide efforts by VHL care teams in Denmark and the Netherlands have 419 
sought to address these issues by providing additional evidence regarding the optimal initiation 420 
and frequency of surveillance regimes.109-113 Kruizinga et al. calculated organ-specific age to 421 
initiate surveillance (and surveillance intervals), which were 0 years/at birth for the adrenal 422 
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glands (4 year interval between screenings), 7 years for the retina (2 year interval), 14 for the 423 
cerebellum (1 year interval), 15 for the spinal cord (1 year interval), 16 for the pancreas (2 year 424 
interval), and 18 for the kidneys (1 year interval).111 These findings represent significant 425 
deviation from current surveillance guidelines particularly in terms of adrenal and retinal 426 
surveillance, with a 6 year later initiation of retinal surveillance and one year longer interval 427 
follow-up, and 5 year earlier initiation of adrenal surveillance with 3 year longer interval follow-428 
up.111 They were also able to calculate the age, 34 years old, at which the probability of 429 
developing a first manifestation of VHL is <5%, representing a reasonable age to stop 430 
surveillance, for instance in at-risk family members of a proband whose disease-causing 431 
mutation cannot be identified.111  432 
Other groups have suggested possible modifications in the current guidelines for other 433 
organs, for example, Poulson et al. found that biennial CNS examinations led to relatively high 434 
rate (7.2%) of interval lesions with clinical consequences, whereas annual screening reduced the 435 
risk to an acceptable rate of 2.7%.113 Binderup et al. pointed out that these and other previous 436 
studies have assumed the risk of new tumor development is constant throughout a VHL patient’s 437 
lifetime, however, risk can vary significantly with age and genotype and depends on the organ 438 
involved.109 They found that tumor development was highest at 30-34 years, and when broken 439 
down by the most common organs affected in their cohort, the risk of retinal tumors was highest 440 
during teenage years (15-19 years) and the risk of cerebellar tumors was highest during the 30s. 441 
Therefore, adherence to surveillance of these organs during those times should be particularly 442 
encouraged. Additionally, they stratified by genotype, and found that carriers of truncating 443 
mutations had significantly higher rates of manifestations compared to missense mutation 444 
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carriers, with the exception of retinal tumors which were significantly less frequent in carriers of 445 
truncating mutations.109 While some argue that surveillance recommendations should not be 446 
influenced by specific mutations as the second hit that results in tumor development is random, 447 
the goal in any hereditary cancer predisposition syndrome is to be able to tailor management 448 
guidelines based on individual factors, such as genotype, environmental stimuli, or other genetic 449 
alterations.  450 
As all of the above mentioned studies represent significant deviations from the current 451 
surveillance guidelines, they would need to be confirmed by larger prospective studies in other 452 
geographic populations before being incorporated into clinical practice.  453 
In terms of practical strategies for increasing adherence to surveillance protocols, it is 454 
crucial for health care providers to set expectations before screening regarding benefits and 455 
limitations, and logistical matters including how and when results will be relayed. It is important 456 
to engage the whole family in this discussion if possible, as studies have shown that family 457 
members tend to take the same stance towards long-term surveillance.90 Families also need to 458 
understand that absence of symptoms is not a reason to delay screening; the variable nature of 459 
the disease within families can create the misconception that only the members who are the most 460 
symptomatic require close follow-up.90,112 It is also important that health care providers adhere to 461 
national guidelines for surveillance because patients given variable advice at different 462 
institutions tend not to fully adhere to the given advice.112  If feasible, a “case manager” 463 
(specially trained nurse practitioner or genetic counselor) for VHL families is advised in order to 464 
serve as a primary contact and help coordinate multidisciplinary care, including medical follow-465 
up and psychosocial needs.112 466 
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The role of patient associations is crucial in disseminating up-to-date information about 467 
rare diseases to patients and physicians. The VHL Alliance, established in 1994, has a worldwide 468 
presence and actively contributes to supporting VHL research and works with experts in the field 469 
to establish current surveillance recommendations (www.vhl.org). There are now National VHL 470 
networks and/or specialized clinical care centers in over 30 countries that offer specialized 471 
medical and psychosocial support and opportunity to connect with VHL patients from around the 472 
world.48,106 Table 4 provides a list of VHL and genetics resources for patients, their caregivers, 473 
and managing physicians.  474 
In summary, VHL is a complex and intriguing disease from a genetic, clinical, and 475 
psychosocial standpoint. It is a disease that spans a breadth of pediatric and adult oncologic 476 
subspecialties and as such providers should be aware of when consider the diagnosis and the 477 
special considerations involved in genetic workup and familial testing. There have been many 478 
advances in the understanding of VHL over the years, and continued discoveries will lend insight 479 
into the treatment of variety of hereditary and sporadic cancers and help optimize all aspects of 480 
care for VHL patients and their families. Strategies may need to adjust as new therapies are 481 
expected to become available, likely on an organ-by-organ basis. For example, for the treatment 482 
of ccRCC, both VHL patients and sporadic patients have enormously benefited from VHL-483 
driven molecular biology, in particular VEGF pathway inhibitors like sunitinib and pazopanib 484 
which currently form the only two first-line therapies recommended for treatment of 485 
metastasized RCC. However, recent FDA approval of immuno-oncological agents like 486 
nivolumab for second-line treatment of advanced renal cell carcinoma114 should be carefully 487 
followed in VHL patients, since presumably a single VHL patient may have hundreds or more 488 
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subclinical lesions throughout their body. Exciting developments in gene therapy offer future 489 
promise for VHL patients,115 but for now surveillance remains the best approach for disease 490 
management.   491 
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Table 1. Indications for consideration of genetic counseling/testing for VHL56,57,61 798 
Simplex Case is Sufficient for Referral  Presence of >1 Tumor is Suggested for Referral 
Retinal/CNS HB Pancreatic cystadenoma 
PCC/PGL PNET 
ELST Epididymal/adnexal cystadenoma** 
Clear-cell RCC* Clear-cell RCC*** 
 799 
*If diagnosed <50 years old or > 1 close relative with clear-cell RCC 800 
** Bilateral papillary cystadenomas of adnexal/broad ligament are pathognomonic for VHL 801 
*** If diagnosed >50 years old or no close relatives clear-cell RCC 802 
 803 









Organization Website  
VHL Family Alliance www.vhl.org 
GeneReviews® -VHL http://www.ncbi.nlm.nih.gov/books/NBK1463/ 
PDQ® Summaries- VHL  http://www.cancer.gov/types/kidney/hp/kidney-genetics-pdq 
National Society of Genetic Counselors  www.nsgc.org 
Genetic Testing Registry http://www.ncbi.nlm.nih.gov/gtr/ 
GeneTests™ https://www.genetests.org/ 
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Table 3. Frequency and Age of Onset of VHL-associated Tumors5,6,48,58 813 
 Mean (range) age 




Retinal HB 25 (1-68) 25-60% 
ELST 22 (12-50) 10-15% 
Craniospinal HB 
(overall) 
30 (9-70) 60-80% 
Cerebellum 33 (9-78) 44-72% 
Brainstem 32 (12-46) 10-25% 
Spinal cord 33 (11-66) 13-50% 
Visceral 
RCC or cysts 39 (13-70) 25-75% 
PCC 27 (5-58) 10-25% 






Unknown (16-46) Unknown  
 814 
* Frequency of PNET is 11-17% whereas that of pancreatic cysts is up to 75%48 815 
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Table 4. VHL Subtypes76,116,117 827 
 828 
VHL Subtype VHL Mutation 
Type 
High Risk Low Risk 




CNS/retinal HB, RCC PCC 




CNS/retinal HB PCC, RCC (risk may 
increased if C3orf10 
remains increased) 




CNS/retinal HB, PCC  RCC 
Type 2B Missense; e.g. 
p.R167Q, 
p.R167W 
CNS/retinal HB, RCC, 
PCC 
 
Type 2C Missense; e.g. 
p.V84L p.L188V 
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Table 5. Suggested VHL Surveillance Guidelines106,109,113   840 
Age Screening Frequency  
0-4 •  Eye/retinal exam with indirect ophthalmoscope  




5-15 Above plus:  
•  Test for plasma free metanephrines, or urinary 
metanephrines using 24-hour urine test  
•  Abdominal u/s from 8yrs or earlier if indicated; 
abdominal MRI or functional imaging scan only if 
biochemical abnormalities found  
•  Audiology assessment; in the case of repeated ear 
infections, MRI with contrast of the internal 
auditory canal  
 
Annually  
                      
Annually                
 
2-3 yrs (1 yr if 
tinnitus, hearing 
loss or vertigo) 
16+ Above plus:  
• Quality ultrasound of abdomen  
•  MRI of abdomen with and without contrast  
•  MRI of brain and cervical spine 
                                  
Annually  
Every 2 yrs  
Every 1-2 yrs  
 841 
 842 
 843 
